De novo design of generalizable allosteric modulators and peptide ligands for G protein coupled receptors
G 蛋白偶联受体的通用变构调节剂和肽配体的从头设计
基本信息
- 批准号:10160902
- 负责人:
- 金额:$ 17.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-05-07 至 2022-01-27
- 项目状态:已结题
- 来源:
- 关键词:AddressAffinityAgonistBindingBinding ProteinsBiologicalBiological AssayBrainC-terminalCell surfaceCommunitiesCustomDNADetergentsDiseaseDisulfidesDrug DesignDrug TargetingEngineeringEscherichia coliExtracellular DomainFDA approvedFamilyFluorescence-Activated Cell SortingG Protein-Coupled Receptor SignalingG-Protein-Coupled ReceptorsGTP-Binding Protein alpha Subunits, GsGTP-Binding ProteinsGeneticGoalsHeterotrimeric GTP-Binding ProteinsIndividualInvestigationLeadLigand BindingLigandsLuciferasesMediatingMethodsModelingMolecularMolecular ConformationN-terminalOligonucleotidesPeptidesPharmaceutical PreparationsProcessProductionProtein EngineeringProtein FamilyProtein SubunitsProteinsReceptor ActivationReporterResearchSignal TransductionSignaling ProteinSiteSourceSpecificityStructureSurfaceSynthetic GenesSystemTechnologyTestingTherapeuticTimeTransmembrane DomainWestern BlottingWorkYeastsbasedeep sequencingdesigndrug discoveryexperimental studyhigh throughput screeningimprovedin vivomimeticsnanobodiesoverexpressionpeptide structureprotein expressionprotein protein interactionprotein purificationprotein structurereceptorreceptor bindingreceptor functionscreeningsmall moleculestructural biologythermostabilitytool
项目摘要
Project Summary
Roughly one third of all FDA approved drugs target G protein coupled receptors (GPCRs), and this protein
family holds myriad therapeutic opportunities yet to be discovered. GPCRs signal through allosteric changes in
protein structure, and there is a large unmet need for effective, highly generalizable tools for conformational
control of these receptors. This project has two Specific Aims, both of which employ computational protein
design with Rosetta to build proteins de novo that bind and modulate GPCR conformation. Upon ligand binding
and activation, GPCRs associate with and signal through G proteins. In the first Aim, we design proteins de
novo which mimic the interaction domain of the endogenous Gα protein subunit. Because the interaction
between receptor and Gα is highly conserved, the protein tools we propose to develop can be applied broadly.
Synthetic genes encoding de novo Gα mimetics have been expressed, and protein was purified from
Escherichia coli. Binding to several different detergent-solubilized GPCRs was demonstrated via pull-down and
Western blotting. Functional Gα mimetic proteins will be structurally characterized and used as templates for
re-engineering a small suite of mimetics for all Gα subtypes. Additionally, we propose to leverage the Gα
mimetics to enhance the expression and purification of GPCRs. To demonstrate this system, we will attempt to
produce three different GPCRs for the first time: super conserved receptor expressed in brain 1-3. In the
second aim, we will design disulfide constrained peptides to serve as agonists and antagonists for all
structure-enabled family B GPCRs. This receptor family recognizes endogenous peptide ligands, and they are
difficult to drug with small molecules. Structures that detail ligand recognition are available for 60% of family B
receptors; we will use these as the basis for de novo design of high-affinity antagonist ligands based on
disulfide-constrained peptides. We will then screen hundreds of thousands of rationally designed de novo
peptides using yeast display, fluorescence activated cell sorting, and deep sequencing. Our unique design
approach enables us to custom tailor the peptide topology so that we can readily convert our antagonists into
high affinity agonists by extending the peptide N-terminus. The efficacy of designed ligands identified via the
high-throughput screen will be assessed individually using a luciferase reporter assay for GPCR signaling. The
research proposed here represents the first time that computational de novo protein design will be applied to
control GPCR conformation. This work has the potential to create valuable tools to empower the GPCR
research community and accelerate discovery of lead therapeutics for many diseases.
项目摘要
FDA批准的所有药物中约有三分之一针对G蛋白偶联受体(GPCRs),而这种蛋白质
家庭拥有无数尚未发现的治疗机会。GPCRs信号通过变构的变化
蛋白质结构,以及对有效的、高度通用的构象分析工具的巨大需求。
对这些受体的控制。这个项目有两个特定的目标,都使用了计算蛋白质
用罗塞塔设计构建结合和调节gpcr构象的蛋白质de nevo。关于配基结合
和激活,GPCRs与G蛋白结合并通过G蛋白传递信号。在第一个目标中,我们设计了蛋白质
NOVO模拟内源Gα蛋白亚基的相互作用结构域。因为这种互动
受体和G-α之间高度保守,我们建议开发的蛋白质工具具有广泛的应用前景。
表达了编码de novo Gα模拟物的合成基因,并从
与几种不同洗涤剂增溶的GPCR结合的通过下拉和
Western blotting。功能性G-α模拟蛋白的结构将被表征并用作模板
重新设计了一套适用于所有Gα亚型的模拟程序。此外,我们建议利用Gα
促进GPCRs的表达和纯化的模拟物。为了演示此系统,我们将尝试
首次产生三种不同的GPCRs:在大脑中表达的超保守受体1-3。在
第二个目标,我们将设计二硫键受限制的多肽,作为所有人的激动剂和拮抗剂。
结构使能的B族GPCRs。这个受体家族识别内源性多肽配体,它们是
很难用小分子药物。B家族中60%的人有详细的配基识别结构
受体;我们将利用这些作为从头设计高亲和力拮抗剂配体的基础
二硫键结合的多肽。然后我们将筛选出成千上万的合理设计的de nevo
多肽采用酵母展示、荧光激活的细胞分选和深度测序。我们独特的设计
方法使我们能够定制多肽拓扑,以便我们可以很容易地将我们的对手转换为
通过延伸多肽N-末端的高亲和力激动剂。设计的配体通过识别的有效性
高通量筛选将使用荧光素酶报告试验对GPCR信号进行单独评估。这个
这里提出的研究代表了计算性从头开始蛋白质设计将首次应用于
控制gpr的构象。这项工作有可能创造出有价值的工具来增强GPCR的能力
研究社区并加速发现针对许多疾病的铅疗法。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Toward complete rational control over protein structure and function through computational design.
- DOI:10.1016/j.sbi.2020.10.015
- 发表时间:2021-03
- 期刊:
- 影响因子:6.8
- 作者:Adolf-Bryfogle J;Teets FD;Bahl CD
- 通讯作者:Bahl CD
Complete Combinatorial Mutational Enumeration of a protein functional site enables sequence-landscape mapping and identifies highly-mutated variants that retain activity.
蛋白质功能位点的完整组合突变枚举可实现序列景观图谱并识别保留活性的高度突变变体。
- DOI:10.21203/rs.3.rs-2248327/v1
- 发表时间:2023
- 期刊:
- 影响因子:0
- 作者:Colom,MireiaSolà;Vucinic,Jelena;Adolf-Bryfogle,Jared;Bowman,JamesW;Verel,Sébastien;Moczygemba,Isabelle;Schiex,Thomas;Simoncini,David;Bahl,ChristopherD
- 通讯作者:Bahl,ChristopherD
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christopher David Bahl其他文献
Christopher David Bahl的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christopher David Bahl', 18)}}的其他基金
Computational de novo design of a disulfide-rich miniprotein synthetic library and its application to engineer binders to neutralizing epitopes on Clostridium difficile toxins TcdA and TcdB
富含二硫键的微型蛋白合成文库的计算从头设计及其在工程粘合剂中的应用,以中和艰难梭菌毒素 TcdA 和 TcdB 上的表位
- 批准号:
10318198 - 财政年份:2020
- 资助金额:
$ 17.98万 - 项目类别:
相似海外基金
Discovery of a High Affinity, Selective and β-arrestin Biased 5-HT7R Agonist
发现高亲和力、选择性和β-抑制蛋白偏向的 5-HT7R 激动剂
- 批准号:
10412227 - 财政年份:2022
- 资助金额:
$ 17.98万 - 项目类别:
Discovery of a High Affinity, Selective and β-arrestin Biased 5-HT7R Agonist
发现高亲和力、选择性和β-抑制蛋白偏向的 5-HT7R 激动剂
- 批准号:
10610473 - 财政年份:2022
- 资助金额:
$ 17.98万 - 项目类别:
Supplement to Discovery of a high affinity, selective and beta-arrestinbiased 5-HT7R Agonist Grant
对高亲和力、选择性和 β 抑制偏向 5-HT7R 激动剂发现的补充补助金
- 批准号:
10799162 - 财政年份:2022
- 资助金额:
$ 17.98万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6639179 - 财政年份:2001
- 资助金额:
$ 17.98万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6724797 - 财政年份:2001
- 资助金额:
$ 17.98万 - 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
- 批准号:
6636512 - 财政年份:2001
- 资助金额:
$ 17.98万 - 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
- 批准号:
6326889 - 财政年份:2001
- 资助金额:
$ 17.98万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6266928 - 财政年份:2001
- 资助金额:
$ 17.98万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6539099 - 财政年份:2001
- 资助金额:
$ 17.98万 - 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
- 批准号:
6520329 - 财政年份:2001
- 资助金额:
$ 17.98万 - 项目类别: